Randomized Trial: No Difference in Major Cardiovascular Outcomes in Patients with Type 2 Diabetes Treated with DPP-4 Inhibitor vs. Sulfonylurea

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Sulfonylureas and Cardiovascular Safety: The Final Verdict? – JAMA (free for a limited period)

Commentary: CAROLINA: No Added Heart Risk With Sulfonylureas – MedPage Today (free registration required)